Abstract

Diabetes mellitus affects over 537 million adults globally, with inadequate glycemic control contributing to severe 
microvascular and macrovascular complications. Conventional insulin therapy, including multiple daily injections 
and continuous subcutaneous insulin infusion, failed to mimic physiological insulin secretion patterns, resulting in 
hypoglycemic episodes and suboptimal glucose homeostasis. Smart insulin patch delivery systems represented an 
emerging biomedical engineering approach that integrates glucose-sensing mechanisms with controlled insulin 
release, offering automated, physiologically responsive treatment modalities. This review critically evaluated the 
biochemical foundations, technological architectures, clinical efficacy, and translational potential of glucose
responsive smart insulin patches for diabetes management. A comprehensive literature search of peer-reviewed 
articles published between 2014 and 2024 was conducted across PubMed, Web of Science, and Scopus databases 
using terms related to glucose-responsive insulin delivery, microneedle patches, and closed-loop systems. Current 
smart patch platforms employ diverse glucose-sensing mechanisms including phenylboronic acid derivatives, 
glucose oxidase enzymatic systems, and concanavalin A lectin-based recognition. Microneedle arrays facilitate 
minimally invasive transdermal delivery while maintaining mechanical integrity and biocompatibility. Preclinical 
studies demonstrated rapid glucose-responsive insulin release within 30 to 60 minutes, sustained euglycemia for 10 
to 20 hours, and reduced hypoglycemic events compared to conventional therapy. However, human clinical trials 
remain limited, with challenges including long-term biocompatibility, sensor drift, and regulatory pathway 
complexity. Glucose-responsive insulin patches demonstrated substantial preclinical promise for physiological 
glycemic control, yet require rigorous clinical validation, standardized performance metrics, and manufacturing 
scalability before clinical implementation.